



Daiichi-Sankyo

Stock code
number
4568

Reference Data

(Consolidated Financial Results for 3Q FY2007)

- [1] Summary of Financial Statement P1
- [2] Currency Rate P1
- [3] Consolidated sales of Global Product P2
- [4] Overseas Sales P2
- [5] Consolidated Segment Information-Business P3
- [6] Consolidated Segment Informations-Area P3
- [7] Domestic Sales P4
- [8] Sales of Overseas Subsidiaries P5
- [9] R&D Pipeline P6

The forecasts of FY2007 announced in November are
NOT revised.

(Figures of non-pharmaceutical subsidiaries are not included)

1. Summary of Financial Statement

(Billions of yen)

	FY2006 Results				FY2007									
	Full year				1st half Results		2nd half Forecast				Full year Forecast			
	3Q YTD				Pharma business * Influence of change in the accounting period Excluded	Pharma business * Influence of change in the accounting period Excluded	3Q Results				3Q YTD Results			
		Pharma business * Influence of change in the accounting period Excluded		Pharma business * Influence of change in the accounting period Excluded			Progress	Pharma business *			Pharma business * Influence of change in the accounting period Excluded	Pharma business * Influence of change in the accounting period Excluded		
Change	<-3.8>		<-0.4>	<-4.8>	<-8.7>	<-4.4>	<-3.0>		<-7.7>	<-2.6>	<-4.8>	<-5.6>	<-5.8>	<-6.5>
Net sales	730.6	621.6	929.5	793.7	443.7	413.2	252.1	58.3%	243.1	432.3	695.8	656.3	876.0	845.5
Cost of sales	208.4	152.9	265.2	190.2	113.2	95.0	68.5	63.6%	60.5	107.8	181.7	155.5	221.0	202.8
Cost of sales ratio	28.5%	24.6%	28.5%	24.0%	25.5%	23.0%	27.2%		24.9%	24.9%	26.1%	23.7%	25.2%	24.0%
Selling, general and administrative	390.3	351.1	528.0	483.4	236.6	225.5	120.7	46.7%	119.6	258.4	357.3	345.1	495.0	483.9
SG&A ratio	53.4%	56.5%	56.8%	60.9%	53.3%	54.6%	47.9%		49.2%	59.8%	51.4%	52.6%	56.5%	57.2%
Research and development	125.3	119.2	170.7	163.3	78.3	77.5	38.8	41.6%	38.5	93.2	117.0	116.0	171.5	170.7
R&D ratio	17.2%	19.2%	18.4%	20.6%	17.6%	18.7%	15.4%		15.9%	21.6%	16.8%	17.7%	19.6%	20.2%
Change	<-1.7>		<-11.9>	<-14.9>	<-19.9>	<-42.7>	<-17.2>		<-19.8>	<-14.0>	<-18.8>	<-32.5>	<-17.4>	<-32.3>
Operating income	132.0	117.6	136.3	120.1	93.9	92.7	62.9	95.1%	63.0	66.1	156.8	155.8	160.0	158.8
/ Net sales	18.1%	18.9%	14.7%	15.1%	21.2%	22.4%	24.9%		25.9%	15.3%	22.5%	23.7%	18.3%	18.8%
Change	<-5.2>		<-4.8>	<-8.0>	<-14.2>	<-35.4>	<-12.8>		<-15.4>	<-10.1>	<-13.6>	<-26.7>	<-12.4>	<-26.1>
Ordinary income	146.1	130.0	152.1	134.5	100.7	99.2	65.3	93.0%	65.5	70.3	166.0	164.8	171.0	169.5
/ Net sales	20.0%	20.9%	16.4%	16.9%	22.7%	24.0%	25.9%		27.0%	16.3%	23.9%	25.1%	19.5%	20.1%
Change	<-4.1>		<-10.4>	<-53.8>	<-9.9>	<-25.2>	<-234.8>		<->	<-240.9>	<-24.1>	<-132.9>	<-27.3>	<-174.8>
Net income	77.7	41.2	78.5	35.3	60.2	57.3	36.2	91.0%	38.7	39.8	96.4	96.0	100.0	97.0
/Net sales	10.6%	6.6%	8.5%	4.4%	13.6%	13.9%	14.3%		15.9%	9.2%	13.9%	14.6%	11.4%	11.5%

*In order to make comparison with the existing businesses in FY2007 easier, "Pharma business" does not include certain figures from the non-pharmaceuticals operations. Thus, it does not meet the figures in the "Consolidated Segment information - Business" section.

【Notes】

1st half of FY2007 (vs. previous year)

• The accounting period of Daiichi Sankyo Europe GmbH (DSE), which is an European subsidiary of the DAIICHI SANKYO Group, for the first nine months of FY2007 was 12 months from January 2007 to December 2007, following a change in its fiscal year-end from December to March.

The net sales, operating income, ordinary income, and net income of DSE for the period from January to March 2007 was ¥14.1 billion, ¥1.8 billion, ¥2.1 billion, and ¥2.0 billion, respectively.

• The accounting period of Daiichi Sankyo INC. (DSI) and Luitpold Pharmaceuticals Inc. (LPI), both of which are U.S. subsidiaries of the DAIICHI SANKYO Group, for the first nine months of FY2006 was 12 months from January 2006 to December 2006, following a change in these companies' fiscal year-end from December to March. The aggregate net sales, operating income, ordinary income, and net income of these subsidiaries for the period from January to March 2006 were ¥31.5 billion, ¥9.0 billion, ¥10.5 billion, and ¥5.8 billion, respectively.

• 2 Latin American subsidiaries are newly included in the scope of consolidation in FY2007.

• DAIICHI SANKYO Group has been in the process of making non-pharmaceutical operations independent of the Group in order to focus resources on the pharmaceutical business. In FY2006, the Company completed various movements which made subsidiaries such as Wakodo Co., Ltd., Fuji Flour Milling Co., Ltd., Daiichi Pure Chemicals Co., Ltd., Daiichi Radioisotope Laboratories, Ltd., Sankyo Agro Co., Ltd., Meguro Chemical Industry Co., Ltd., Sankyo Yell Yakuhin Co., Ltd., and Daiichi Medical Co., Ltd. independent of the Group.

The Company also made Daiichi Fine Chemical Co., Ltd. and Saitama Daiichi Pharmaceuticals Ltd. independent of the group in the 1st half of FY2007.

FY2007 Forecast

The forecasts of FY2007 announced in November are NOT revised.

Figures of non-pharmaceutical subsidiaries are not included in the forecast of 2nd half.

2. Currency rate

	FY2006 Results		FY2007		
	3Q YTD	Full Year	3Q YTD		2nd half Forecast
			1st half Results	(issued in Nov.)	
Yen/USD (Average)	116.4	117.0	119.3	117.3	115
Yen/EUR (Average)	144.2	146.1	160.4	161.2	155

【Estimated impact of currency rate fluctuation for FY2007】

1st half Results

Yen was approximately 5 yen and 20 yen weaker than originally estimated against USD and EUR, respectively. The effect of gains on currency exchange brought by weakening of the yen was net sales of ¥11.4 billion and operating income of ¥1.2 billion.

3Q YTD Results

Yen was weaker than the originally estimated currency rate (1USD = ¥115, 1EUR = ¥140). The effect of gains on currency exchange brought by weakening of the yen was net sales of ¥13.6 billion and operating income of ¥1.1 billion.

Full Year Forecast

A one yen per USD change in currency rate has an impact of approximately ¥1.8 billion and ¥0.3 billion on annual net sales and operating income, respectively.

A one yen per EUR change in currency rate has an impact of approximately ¥0.5 billion on annual net sale.

3. Consolidated sales of Global Products

(Billions of yen)

	FY2006 Results			FY2007												
	3Q YTD	Full Year		1st half Results		2nd half Forecast			Full Year Forecast							
		Change %		Change %	Change %	Influence of change in the accounting period Excluded	3Q Results		Change %	Influence of change in the accounting period Excluded	Change %	Influence of change in the accounting period Excluded				
							Change %	Progress								
Olmesartan* [antihypertensive]	123.7	160.3	73.5%	96.6	(15.1%)	32.1%	54.1	35.8%	51.3%	105.4	150.7	(21.8%)	33.4%	202.0	(26.0%)	35.2%
Japan: Olmetec	33.0	42.2	65.4%	26.4	36.0%	-	17.6	29.5%	50.9%	34.6	44.0	33.3%	-	61.0	44.5%	-
U.S.: Benicar/Benicar HCT*	73.0	92.8	84.4%	44.5	(-16.5%)	18.1%	24.1	22.0%	54.4%	44.3	68.6	(-6.1%)	19.4%	88.8	(-4.3%)	15.1%
AZOR	-	-	-	-	-	-	1.9	-	58.9%	3.2	1.9	-	-	3.2	-	-
Europe: Olmetec/Olmetec Plus**	15.8	22.5	53.2%	22.3	(121.6%)	58.0%	8.3	45.0%	42.1%	19.7	30.6	(93.8%)	53.3%	42.0	(86.4%)	58.1%
Others	1.9	2.8	56.2%	3.4	189.6%	-	2.2	199.0%	61.2%	3.6	5.6	193.1%	-	7.0	148.9%	-
Levofloxacin [synthetic antibacterial agent]	81.3	104.1	2.6%	52.9	8.4%	-	32.2	-1.0%	56.3%	57.1	85.1	4.6%	-	110.0	5.6%	-
Japan: Cravit	38.0	46.7	-6.9%	22.1	5.1%	-	15.5	-8.5%	53.6%	28.9	37.6	-1.0%	-	51.0	9.1%	-
Exports	29.6	38.4	10.6%	21.6	11.9%	-	11.8	14.3%	65.9%	17.9	33.4	12.7%	-	39.5	2.8%	-
Royalty	13.7	19.0	14.4%	9.2	8.6%	-	4.9	-6.9%	47.3%	10.3	14.1	2.7%	-	19.5	2.8%	-
Pravastatin [antihyperlipidemic agent]	76.6	93.5	-34.7%	40.3	(-22.4%)	-25.5%	21.6	-11.7%	55.9%	38.7	61.9	(-19.0%)	-21.3%	79.0	(-15.5%)	-17.3%
Japan: Mevalotin	54.8	67.8	-9.9%	31.7	-9.0%	-	18.2	-8.7%	56.5%	32.3	49.9	-8.9%	-	64.0	-5.6%	-
Europe**	4.7	6.0	9.1%	4.1	(26.4%)	-22.7%	1.2	-13.4%	59.2%	2.1	5.4	(14.4%)	-19.8%	6.2	(3.4%)	-23.4%
Exports	17.1	19.8	-68.4%	4.5	-67.7%	-	2.2	-34.0%	50.3%	4.3	6.7	-61.2%	-	8.8	-55.5%	-

* FY2006 results for Benicar / Benicar HCT are fifteen-months totals. (January 2006 - March 2007)

Three-months results (January 2006 - March 2006) is ¥15.6 billion (\$135mil).

* * FY2007 3Q results for Olmetec / Olmetec Plus and Mevalotin are twelve-months totals. (January 2007 - December 2007)

Three-months results (January 2007 - March 2007) are ¥6.4 billion (€40mil) and ¥1.6 billion (€10mil), respectively.

4. Overseas sales

(Billions of yen)

	FY2006 Results			FY2007									
	3Q YTD	Full Year		1st half Results		2nd half Forecast			Full year Forecast				
		Change %		Change %	Change %	Change %	3Q Results		Change %	Change %	Change %	Change %	
							Change %	Change %					
North America*	189.0	241.9	32.4%	111.2	-17.6%	62.2	15.0%	108.8	173.4	-8.3%	220.0	-9.0%	
Europe**	63.6	84.3	-14.3%	56.7	27.3%	19.4	2.0%	41.3	76.2	19.7%	98.0	16.2%	
Others	22.8	30.5	16.5%	20.6	36.1%	10.7	38.3%	13.4	31.3	36.9%	34.0	11.4%	
Overseas sales	275.5	356.7	16.1%	188.5	-3.2%	92.4	14.2%	163.5	280.9	1.9%	352.0	-1.3%	
/ Net sales	37.7%	38.4%		42.5%		36.6%		37.8%	40.4%		40.2%		

Others: China, Korea, Thailand, Taiwan, Brazil, Venezuela etc.

*FY2006

The accounting period of Daiichi Sankyo INC. (DSI) and Luitpold Pharmaceuticals Inc. (LPI), both of which are U.S. subsidiaries of the DAIICHI SANKYO Group, was 15 months from January 2006 to March 2007, following a change in these companies' fiscal year-end from December to March. The aggregate net sales of these subsidiaries for the period from January to March 2006 were ¥31.5 billion.

**FY2007

The accounting period of Daiichi Sankyo Europe GmbH (DSE) is 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March. The net sales of DSE for the period from January to March 2007 was ¥14.1 billion.

5. Consolidated Segment information - Business

(Billions of yen)

		FY2006 Results			
		Full Year			
		3Q YTD			
		1st half	3Q		
	Domestic	215.2	132.8	348.0	433.4
	Overseas*	185.2	77.0	262.2	338.1
	OTC drugs	24.6	15.1	39.7	47.9
	Pharmaceuticals	441.4	225.5	666.9	837.1
	Other	44.5	19.3	63.8	92.4
Consolidated Sales		485.8	244.8	730.6	929.5
	Pharmaceuticals	75.9	52.8	128.7	131.4
	Other	2.3	0.5	2.8	4.4
	Consolidated Operating income	78.4	53.6	132.0	136.3

		FY2007 Results					
		3Q YTD					
		1st half		3Q			
			Change %		Change %		Change %
		214.5	-0.3%	135.8	2.3%	350.3	0.7%
		184.7	-0.3%	89.4	16.2%	274.1	4.6%
		24.4	-0.6%	15.2	0.1%	39.6	-0.4%
		424.0	-3.9%	241.2	7.0%	665.2	-0.2%
		19.7	-55.7%	10.9	-43.4%	30.6	-52.0%
Consolidated Sales		443.7	-8.7%	252.1	3.0%	695.8	-4.8%
		94.2	24.1%	62.5	18.4%	156.7	21.7%
		-0.4	-	0.3	-36.8%	-0.1	-
		93.9	19.9%	62.9	17.2%	156.8	18.8%

*FY2006

The accounting period of Daiichi Sankyo INC. (DSI) and Luitpold Pharmaceuticals Inc. (LPI), both of which are U.S. subsidiaries of the DAICHI SANKYO Group, was 15 months from January 2006 to March 2007, following a change in these companies' fiscal year-end from December to March. The aggregate operating results of these subsidiaries for the period from January to March 2006 were net sales of ¥31.5 billion and operating income of ¥9.0 billion.

*FY2007

The accounting period of Daiichi Sankyo Europe GmbH (DSE) is 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March. The operating results of DSE for the period from January to March 2007 was net sales of ¥14.1 billion and operating income of ¥1.8 billion.

6. Consolidated Segment information - Area

(Billions of yen)

		FY2006 Results							
		Full Year							
		3Q YTD							
		1st half	%	3Q	%		%		%
	Japan	342.0	70.4%	187.4	76.6%	529.4	72.5%	667.8	71.9%
	North America*	108.5	22.3%	41.0	16.7%	149.5	20.5%	191.5	20.6%
	Europe**	27.3	5.6%	11.9	4.9%	39.2	5.4%	53.4	5.7%
	Other	8.0	1.6%	4.5	1.8%	12.5	1.7%	16.8	1.8%
	Consolidated Sales		485.8	100.0%	244.8	100.0%	730.6	100.0%	929.5
	Japan	71.6		43.7		115.3		112.7	
	North America	33.9		0.5		34.4		37.3	
	Europe	5.4		1.8		7.2		6.8	
	Other	0.3		0.3		0.6		0.8	
	Consolidated Operating income		78.4		53.6		132.0		136.3

		FY2007 Results								
		3Q YTD								
		1st half		3Q						
			%	Change %		%	Change %		%	Change %
		295.4	66.6%	-13.6%	179.7	71.3%	-4.1%	475.1	68.3%	-10.3%
		89.7	20.2%	-17.4%	51.1	20.3%	24.7%	140.8	20.2%	-5.8%
		45.3	10.2%	66.0%	14.5	5.7%	21.6%	59.8	8.6%	52.5%
		13.3	3.0%	66.5%	6.8	2.7%	52.7%	20.1	2.9%	61.5%
	Consolidated Sales		443.7	100.0%	-8.7%	252.1	100.0%	3.0%	695.8	100.0%
		69.4			47.3			116.7		
		22.5			12.5			35.0		
		3.4			1.4			4.8		
		1.3			0.7			2.0		
Consolidated Operating income		93.9			62.9			156.8		

*FY2006

The accounting period of Daiichi Sankyo INC. (DSI) and Luitpold Pharmaceuticals Inc. (LPI), both of which are U.S. subsidiaries of the DAICHI SANKYO Group, was 15 months from January 2006 to March 2007, following a change in these companies' fiscal year-end from December to March. The aggregate operating results of these subsidiaries for the period from January to March 2006 were net sales of ¥31.5 billion and operating income of ¥9.0 billion.

**FY2007

The accounting period of Daiichi Sankyo Europe GmbH (DSE) is 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March. The operating results of DSE for the period from January to March 2007 was net sales of ¥14.1 billion and operating income of ¥1.8 billion.

7. Domestic Sales

Sales of main ethical pharmaceuticals

(Billions of yen)

	FY2006 Results			FY2007										
	Full Year			1st half Results		2nd half Forecast			Full Year Forecast					
	3Q	YTD	YoY %	YoY %	3Q			3Q YTD		YoY changes	YoY %			
					Results	YoY %	Progress	Results	YoY %					
Total net sales of ethical pharmaceuticals	339.0	420.4	1.8%	211.0	2.4%	131.9	-0.7%	56.9%	232.0	342.9	1.2%	443.0	22.6	5.4%
Cardiovascular disease-related field														
Olmetec (antihypertensive)	33.0	42.2	65.4%	26.4	36.0%	17.6	29.5%	50.9%	34.6	44.0	33.3%	61.0	18.8	44.5%
Calblock (antihypertensive)	6.9	8.8	38.0%	4.8	17.2%	3.0	10.2%	45.1%	6.7	7.8	14.4%	11.5	2.7	31.0%
Artist (long-acting beta-blocker)	15.4	19.3	5.9%	10.6	10.2%	6.0	3.7%	52.3%	11.4	16.5	7.8%	22.0	2.7	14.0%
Mevalotin (antihyperlipidemic agent)	54.8	67.8	-9.9%	31.7	-9.0%	18.2	-8.7%	56.5%	32.3	49.9	-8.9%	64.0	-3.8	-5.6%
Kremezin (treatment for chronic renal failure)	9.5	12.2	-6.4%	6.2	1.6%	3.5	1.8%	51.8%	6.8	9.7	1.7%	13.0	0.8	6.7%
Hanp (treatment for acute cardiac failure)	7.1	9.2	5.8%	4.5	7.8%	2.9	-1.7%	53.1%	5.5	7.4	3.8%	10.0	0.8	8.9%
Livalo (antihyperlipidemic agent)	4.0	5.1	23.9%	2.6	6.7%	1.6	3.0%	48.1%	3.4	4.2	5.3%	6.0	0.9	16.9%
Sunrhythm (antiarrhythmic agent)	9.4	11.7	-1.3%	6.2	4.5%	3.4	-2.4%	58.7%	5.8	9.6	1.9%	12.0	0.3	2.3%
Bepricor (antiarrhythmic and antianginal agent)	1.8	2.3	25.8%	1.3	18.8%	0.8	19.2%	56.4%	1.4	2.1	18.9%	2.7	0.4	17.3%
Fastic (antidiabetic agent)	4.2	5.4	0.6%	2.6	-3.0%	1.5	-5.6%	61.4%	2.4	4.1	-3.9%	5.0	-0.4	-7.3%
Infectious diseases / bone and joint diseases / immunological allergic diseases / urology														
Cravit (synthetic antibacterial agent)	37.9	46.7	-6.9%	22.1	5.1%	15.5	-8.5%	53.6%	28.9	37.6	-1.0%	51.0	4.3	9.1%
Loxonin (non-steroidal analgesic and anti-inflammatory agent)	23.9	30.9	8.0%	16.4	9.7%	9.8	9.0%	52.7%	18.6	26.2	9.4%	35.0	4.1	13.2%
Mobic (non-steroidal anti-inflammatory agent)	8.6	10.7	0.7%	5.4	-0.5%	2.9	-10.6%	46.7%	6.1	8.2	-4.2%	11.5	0.8	7.8%
Urief (treatment for dysuria)	1.7	2.3	-	2.3	120.9%	1.7	145.4%	32.9%	5.2	4.0	130.7%	7.5	5.2	231.4%
Zyrtec (allergy drug)	8.3	12.0	-4.8%	4.5	-11.0%	2.7	-18.4%	48.5%	5.5	7.2	-13.9%	10.0	-2.0	-16.4%
Contrast agents / cancer / Gastric diseases														
Omnipaque (contrast agent)	26.2	31.5	-9.1%	15.9	-2.7%	9.2	-6.3%	57.4%	16.1	25.1	-4.0%	32.0	0.5	1.5%
Omniscan (contrast medium for MRI)	4.3	5.2	-2.6%	2.5	-8.5%	1.3	-21.1%	55.6%	2.3	3.8	-13.3%	4.8	-0.4	-8.5%
Topotecin (anticancer agent)	4.3	5.4	12.1%	3.1	17.8%	1.7	4.0%	59.8%	2.9	4.8	12.4%	6.0	0.6	10.5%
Krestin (anticancer agent)	3.0	3.8	-18.2%	1.6	-16.9%	0.9	-15.2%	57.0%	1.6	2.5	-16.3%	3.2	-0.6	-15.8%
Feron (interferon beta)	3.2	4.0	9.6%	1.9	-1.2%	1.0	-27.2%	34.5%	2.8	2.9	-11.9%	4.7	0.7	17.3%

Sales of main OTC drugs

(Billions of yen)

	FY2006 Results			FY2007										
	Full Year			1st half Results		2nd half Forecast			Full Year Forecast					
	3Q	YTD	YoY %	YoY %	3Q			3Q YTD		YoY changes	YoY %			
					Results	YoY %	Progress	Results	YoY %					
Total net sales of OTC drugs	39.7	47.9	-	24.4	-0.6%	15.2	0.1%	55.0%	27.6	39.6	-0.4%	52.0	4.0	8.4%
LuLu series	8.8	10.0	7.7%	4.8	-9.5%	3.7	3.4%	62.4%	5.9	8.5	-4.3%	10.7	0.7	6.7%
Gaster 10	3.1	3.6	-	1.7	0.2%	1.0	-28.9%	50.6%	2.0	2.7	-13.1%	3.7	0.1	3.1%
Shin-Sankyo Ichoyaku series	2.3	3.0	2.2%	1.3	-7.6%	1.3	39.1%	66.8%	2.0	2.6	10.9%	3.3	0.3	11.7%
Patecs series	1.6	1.9	-3.5%	1.8	61.4%	0.7	41.1%	50.8%	1.4	2.5	55.3%	3.2	1.3	66.7%
Transino	-	-	-	1.4	-	0.7	-	35.3%	2.0	2.1	-	3.4	3.4	-

Export sales of main products

(Billions of yen)

	FY2006 Results			FY2007										
	Full Year			1st half Results	2nd half Forecast			Full Year Forecast			YoY changes	YoY %		
	3Q	YTD	YoY %		3Q			3Q YTD						
				Results	YoY %	Progress	Results	YoY %	YoY %	YoY %				
Levofloxacin (synthetic antibacterial agent)	25.0	32.4	9.6%	17.1	5.0%	9.8	13.0%	66.0%	14.9	27.0	7.8%	32.0	-0.4	-1.1%
Pravastatin (antihyperlipidemic agent)	18.3	21.6	-66.6%	3.3	-77.7%	1.5	-57.6%	55.1%	2.7	4.8	-73.8%	6.0	-15.6	-72.2%

8. Sales of Overseas Subsidiaries

U.S. subsidiaries—net sales of main products

(Billions of yen)

	FY2006 Results			FY2007											YoY % excluding the impact of change in the accounting period	
	Full Year			1st half Results	2nd half Forecast			Full Year Forecast			YoY changes	YoY %	3Q YTD	Full Year		
	3Q	YTD	YoY %		3Q			3Q YTD								
				Results	YoY %	Progress	Results	YoY %	YoY %	YoY %						
DAIICHI SANKYO INC. (DSI)	101.5	130.4	70.3%	65.1	-11.6%	37.6	35.2%	57.1%	65.9	102.7	1.3%	131.0	0.6	0.4%	25.4%	18.1%
Benicar / Benicar HCT (antihypertensive) (\$ million)	73.0 (627)	92.8 (793)	84.4% 73.9%	44.5 (373)	-16.5% -18.9%	24.1 (212)	22.0% 26.9%	54.4% 55.2%	44.3 (383)	68.6 (585)	-6.1% -6.7%	88.8 (756)	-4.0 (-36)	-4.3% -4.6%	19.4% 18.7%	15.1% 15.0%
Azor (antihypertensive) (\$ million)	-	-	-	-	-	1.9 (16)	-	58.9% 56.5%	3.2 (28)	1.9 (16)	-	3.2 (28)	3.2 (28)	-	-	-
Welchol (antihyperlipidemic agent / treatment for type 2 diabetes) (\$ million)	17.9 (154)	23.2 (198)	56.8% 48.1%	11.4 (96)	-13.1% -15.6%	6.2 (55)	29.7% 33.5%	49.4% 49.8%	12.6 (109)	17.6 (150)	-1.7% -2.5%	24.0 (205)	0.8 (7)	3.4% 3.5%	25.8% 25.0%	24.3% 24.8%
Floxin Otic (antibiotic eardrops) (\$ million)	6.2 (53)	8.2 (71)	33.8% 29.7%	5.4 (45)	21.2% 17.7%	0.2 (3)	-87.6% -81.5%	19.3% 31.7%	1.1 (9)	5.6 (48)	-8.8% -8.8%	6.5 (54)	-1.7 (-17)	-21.2% -24.1%	-	-
Evoxac (treatment of dry-mouth) (\$ million)	2.1 (18)	2.9 (25)	22.5% 18.7%	2.1 (18)	60.8% 56.2%	1.1 (10)	39.5% 40.3%	65.3% 66.3%	1.7 (14)	3.2 (27)	52.7% 50.1%	3.8 (32)	0.9 (7)	29.1% 28.6%	-	-
Luitpold Pharmaceuticals, Inc. (LPI)	48.1	61.0	54.5%	24.6	-29.6%	13.5	2.4%	60.2%	22.4	38.1	-20.9%	47.0	-14.0	-23.0%	5.4%	-4.2%
Venofor (treatment for iron deficiency anemia) (\$ million)	29.1 (250)	37.7 (322)	66.7% 57.1%	14.8 (124)	-28.4% -30.4%	8.2 (72)	-3.7% -0.0%	59.6% 59.4%	13.7 (121)	23.0 (196)	-21.2% -21.7%	28.5 (245)	-9.2 (-77)	-24.4% -23.9%	3.3% 2.7%	-7.5% -6.7%

FY2006 results for DSI, Benicar / Benicar HCT, Welchol, LPI and Venofor are fifteen-months totals. (January 2006 - March 2007)

Three-months results (January 2006 - March 2006) are ¥19.5 billion, ¥15.6 billion (\$135mil), ¥3.9 billion (\$33mil), ¥12.0 billion and ¥6.8 billion (\$59mil), respectively.

European subsidiaries—net sales of main products

(Billions of yen)

	FY2006 Results			FY2007											YoY % excluding the impact of change in the accounting period	
	Full Year			1st half Results	2nd half Forecast			Full Year Forecast			YoY changes	YoY %	3Q YTD	Full Year		
	3Q	YTD	YoY %		3Q			3Q YTD								
				Results	YoY %	Progress	Results	YoY %	YoY %	YoY %						
DAIICHI SANKYO EUROPE GmbH (DSE)	37.7	51.6	17.8%	45.3	71.1%	14.5	28.8%	45.7%	31.7	59.8	58.5%	77.0	25.4	49.1%	20.3%	21.7%
Olmotec / Olmetec Plus (antihypertensive) (€ million)	15.8 (109)	22.5 (154)	53.2% 44.1%	22.3 (139)	121.6% 96.5%	8.3 (51)	45.0% 33.4%	42.1% 39.8%	19.7 (127)	30.6 (190)	93.8% 74.5%	42.0 (266)	19.5 (112)	86.4% 72.7%	53.3% 36.7%	58.1% 46.7%
Mevalotin (antihyperlipidemic agent) (€ million)	4.7 (32)	6.0 (41)	9.1% 2.6%	4.1 (26)	26.4% 12.1%	1.2 (7)	-13.4% -21.4%	59.2% 55.5%	2.1 (13)	5.4 (33)	14.4% 2.3%	6.2 (39)	0.2 (-2)	3.4% -4.5%	-19.8% -28.6%	-23.4% -29.0%

3Q YTD results of FY2007 for DSE, Olmetec / Olmetec Plus, and Mevalotin are twelve-months totals. (January 2007 - December 2007)

Three-months results (January 2007 - March 2007) are ¥14.1 billion, ¥6.4 billion (€40mil) and ¥1.6 billion (€10mil), respectively.

9.R&D Pipeline (Change from the announcement of November 2007)

Development Stage

Development Code Number	Before Change	After Change	Remarks
CS-747	US: Phase3	US: Application	· Anti-platelet agent
CS-8080	—	US/EU:Phase1	· Anti-arteriosclerosis
Welchol DM	US: Application	US: Approval	· Anti-type II diabetic
DU-6859a (Gracevit)	Japan: Application	Japan: Approval	· New quinolone
levofloxacin high-dose	Japan: Phase3	Japan: Application	· New quinolone
levofloxacin injection	Japan: Phase2	Japan: Phase3	· New quinolone
DX-619	US/EU/JP:Phase1	—	· New quinolone · Daiichi Sankyo Group withdrew from this project based on portfolio of research and development.
CS-758	US/EU:Phase1	—	· Azole antifungal · Daiichi Sankyo Group withdrew from this project based on portfolio of research and development.
SUN 0588r	US: Application	US: Approval	· Hyperphenylalaninemia · licensed-out to BioMarin
	—	EU: Application	